RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2002; 88(04): 698-699
DOI: 10.1055/s-0037-1613284
DOI: 10.1055/s-0037-1613284
Letters to the Editor
Myocardial Infarction Occurring in a Case of Acquired Haemophilia During the Treatment Course with Recombinant Activated Factor VII
Weitere Informationen
Publikationsverlauf
Received
22. April 2002
Accepted after revision
04. Juni 2002
Publikationsdatum:
09. Dezember 2017 (online)
-
References
- 1 Hedner U. Factor VIIa in the treatment of hemophilia. Blood Coagul Fibrinolysis 1990; 01: 307-17.
- 2 Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 09 (Suppl. 01) 119-28.
- 3 Hay C, Négrier C, Ludlam C. the treatment of bleeding in acquired hemophilia with recombinant factor VIIa : a multicentre study. Thromb Haemost 1997; 78: 1463-7.
- 4 Nicolaisen E. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998; 09 (Suppl. 01) 119-23.
- 5 Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-2.
- 6 Poon M-C, d’Oiron R. and the International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Recombinant activated factor VII (novoseven) treatment of platelet-related bleeding disorders. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 01) S55-68.
- 7 Roberts H. Clinical experience with activated factor VIIa: focus on safety aspects. Blood Coagul Fibrinolysis 1998; 09 (Suppl. 01) 115-8.
- 8 Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 2001; 08 (05) 312-5.
- 9 Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novoseven) in a patient with hemophilia A and inhibitor. Thromb Haemost 2000; 82: 1775-6.
- 10 Badimon J, Zaman A, Helft G, Fayad Z, Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost 1999; 82 (02) 997-1004.
- 11 Fuster V, Fallon J, Nemerson Y. Lancet. 1996; 348 (Suppl. 01) S7-10.
- 12 Ardissino D, Merlini P, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-71.
- 13 Badimon J, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro J, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of TFPI on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
- 14 Ardissino D, Merlini PA, Bauer KA, Bramucci E, Ferrario M, Coppola R, Fetiveau R, Lucreziotti S, Rosenberg RD, Mannucci PM. Thrombogenic potential of human coronary atherosclerotic plaques. Blood 2001; 98 (09) 2726-9.
- 15 Jansen M, Schmaldienst S, Banyal S, Quehenberger P, Pabinger I, Derfler K, Hörl WH, Knöbl P. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112: 91-7.
- 16 Guillet B, Kriaa F, Huysse MG, Proulle V, George C, Tchernia G, D’Oiron R, Laurian Y, Charpentier B, Lambert T, Dreyfus M. Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia. Br J Haematol 2001; 114: 837-44.